|
|
||||||||
J Thorac Cardiovasc Surg 2000;119:745-751
© 2000 The American Association for Thoracic Surgery
SURGERY FOR CONGENITAL HEART DISEASE |
From the Departments of Pediatric Cardiology and Congenital Heart Diseasea and Cardiac Surgery,b German Heart Center, Technical University, Munich, Germany.
Address for reprints: G. Balling, MD, Deutsches Herzzentrum München, Klinik für Kinderkardiologie und angeborene Herzfehler,-Klinik an der Technischen Universität München-, Lazarettstrasse 36, D-80636 München, Germany (E-mail: Balling{at}DHM.mhn.de ).
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
The true incidence of cardiac thrombi and thromboembolic events is unknown. Moreover, no consensus is found in the literature regarding the tools for diagnosis of cardiac thrombi and the indication and optimal strategy preventing thromboembolism.
6
The aim of our study was to evaluate the occurrence of intracardiac thrombi and to identify predisposing risk factors to optimize diagnostic and therapeutic strategies for patients after the Fontan operation.
Because of the unexpected high occurrence of intracardiac thrombosis in this study, we decided to publish these preliminary data, which are in everyones interest.
| Patients and methods |
|---|
|
|
|---|
Follow-up data were obtained by reviewing each patients medical records. Besides a thorough physical examination, the medical examinations consisted of electrocardiography, 24-hour ambulatory electrocardiography, transthoracic and transesophageal echocardiography (TEE), cardiac catheterization, and laboratory testing.
The preoperative diagnosis included various forms of tricuspid atresia in 23 patients, double-inlet left ventricle in 21, mitral atresia in 4, and a complex type of a univentricular heart in 4 (Table I).
|
The laboratory protocol included measurements of hematologic parameters (red blood cell count and hematocrit level), serum protein, albumin, and renal and liver function parameters (serum alkaline phosphatase, gamma-glutamyl transferase, alanine transaminase, aspartate transaminase, and total bilirubin), as well as the coagulation status (prothrombin time, international normalized ratio [INR], fibrinogen, antithrombin III, activated partial thromboplastin time, protein C, and protein S). All laboratory tests were done at the same time as TEE evaluation.
The transthoracic echocardiography, including cross-sectional view, pulse wave and continuous wave Doppler scanning, and color flow mapping, was evaluated by two experienced investigators with a Vingmed ultrasonographic system (GE Vingmed Ultrasound AS; Strandpromenaden, Horten, Norway) by using a 5.0-, 3.5-, or 2.5-MHz phased-array transducer. The TEE study was performed after achievement of local anesthesia in 27 patients and after achievement of general anesthesia and intubation in the remaining 25 patients. A Vingmed 7.5-MHz mechanical multiplane pediatric probe was used for all examinations with local anesthesia, and a Vingmed 5-MHz mechanical multiplane adult probe was used for those with general anesthesia. All examinations were done by the same physician, and all tapes were reviewed independently by another experienced investigator blinded for the initial outcome.
A thrombus was defined as any localized echogenic mass within the lumen of the left or right atrium or any other intracardiac or extracardiac location with a visible basis to a heart structure. The mass had to be seen in at least two different orthogonal planes. Furthermore, ventricular and atrioventricular valve function, eventual right-to-left shunt at the atrial level, and spontaneous echocardiographic contrast, which is regarded as a marker for stagnant blood flow, were documented. The ventricular function was classified as good, fair, or poor, and aortic and atrioventricular valve regurgitation was classified as absent, mild, moderate, or severe.
Cardiac catheterization was performed in 43 patients. The exclusion criterion for catheterization was newly diagnosed thrombus formation. A minimum of a 3-month interval of oral anticoagulation therapy was regarded to be sufficient to avoid potential complications provoked by a thrombus during atrial catheterization. The study included measurement of pressures and oxygen saturations within the superior and inferior caval veins, the right and left atria, the pulmonary artery system on the ventricular level, and the aorta. Cardiac output was calculated by the Fick method with measured oxygen consumption values. Biplane angiocardiograms of the systemic veins, the right atrium, the pulmonary artery, the ventricle, and the aorta were obtained.
Analysis of data
For statistical analysis, the measured values are reported as means ± SD, median, and range when appropriate. Patients were grouped by the presence or absence of an atrial thrombus. Data was compared by computer-assisted analysis (StatView; Abacus Concepts, Inc, Berkeley, Calif) by using the Mann-Whitney U test or contingency tables (the Fisher exact P test).
| Results |
|---|
|
|
|---|
According to the functional status for congenital heart disease,
7 27 patients were in class I, 17 in class II, 6 in class III, and 2 in class IV. No significant differences could be shown between the functional status of the patients with or without intracardiac thrombus formation (11 in class I and 6 in class II).
Five (12%) patients had refractory protein-losing enteropathy, and another 4 patients had a history of recurrent effusions or ascites but normal serum albumin and
1-antitrypsin levels.
These findings and others, such as sex, type of underlying heart disease, age at first Fontan operation, type of Fontan modification, follow-up interval, presence of cyanosis, or cardiac index, were not significantly different between the patients with or without intracardiac thrombi (Table II).
|
The standard electrocardiographic recordings showed sinus rhythm in 30 patients, intermittent atrial tachycardia in 18 patients, and permanent atrial arrhythmia in another 3 patients. One had an atrioventricular universal pacemaker implanted. A history of significant atrial arrhythmia, documented by 24-hour ambulatory monitoring, was present in 26 patients during the last 12 months. In 9 of these 26 patients a thrombus formation could be detected, but no statistically significant difference between patients with or without arrhythmias could be found.
Laboratory findings of all patients are listed in Table III, and catheterization data were available in 43 patients (Table IV). There was no statistically significant difference in pressure and calculated parameters between the patients with or without intracardiac thrombus.
|
|
By using TEE, spontaneous contrast in the right atrium or within the Fontan connection was documented in 34 (65%) patients. The occurrence of spontaneous microcavitations in the atrium did not differ significantly between patients with or without thrombus formation. Furthermore, no significant difference was found between the two groups regarding atrioventricular function and ventricular function (Table V).
|
| Discussion |
|---|
|
|
|---|
In our series of 52 patients after Fontan-type operations, we found a high occurrence rate (33%) of intracardiac thrombi. In all but one patient transthoracic echocardiography before TEE was unable to identify a thrombus. All thrombi were detected within the right atrium, and only one was additionally found in the left atrium close to the mitral valve. Location of intracardiac thrombi may also occur in the systemic ventricle, rudimentary ventricle, pulmonary artery, or pulmonary artery stump after its distal ligation,
9-12 but not in our study so far.
The symptoms of thrombus formation include venous obstruction, progressive cyanosis, paradoxic emboli to the cerebral or peripheral circulation (if right-to-left atrial shunt is present), or atrial tachyarrhythmia.
13-15 One of our patients had a history of pulmonary embolization, and 3 others had a history of systemic or cerebrovascular embolization. The source of thromboembolism remained unknown, but cardiac anatomy was not investigated by TEE at that time. None of our patients had acute clinical signs of thromboembolic events at the time of investigation, which was mandatory for inclusion into the study. In a retrospective study, Rosenthal and coworkers
9 reported that approximately 43% of the patients with thrombi were asymptomatic. However, 21% of the patients in whom a thrombus formation was previously demonstrated died of a thromboembolic event.
Predisposing risk factors for the development of thrombi and subsequent embolization are a slow and nonpulsatile flow through the caval veins; a poorly contracting, enlarged, and thickened atrium with or without arrhythmias; a small transpulmonary gradient that decreases flow within the tunnel; a low cardiac output with or without atrioventricular valve regurgitation; or an obstructed conduit or a complex baffling because of unusual venous return.
16
The overall reported incidence of intracardiac thrombus formation after the Fontan operation identified by TEE ranges has been shown to be between 6% and 44%,
17-21 but the number of the investigated patients was small and selected for various problems (n = 9-30 patients, Table VI). Despite this, TEE is rarely used for postoperative follow-up.
|
There is a substantial incidence of early and late arrhythmias after the various modifications of the Fontan procedure.
22,23 Parallel to previous TEE studies,
18,19 we could not show any consistency between thrombus formation and arrhythmias or the type of Fontan modification.
Abnormalities of the clotting system, mainly protein C or protein S deficiency, reduced concentration of antithrombin III, and elevated activity of the von Willebrand factor may additionally be involved in prothrombotic reactions in patients having undergone a Fontan operation,
3,15,20 although it failed in this study to be a prognostic risk factor. This was because the number of patients with clotting abnormalities was not significantly different in the groups with and without intracardiac thrombi.
Specific hemodynamic data, such as blood flow, saturation, atrial pressure, and pulmonary resistance or obstructions, did not differ significantly in patients with or without thrombus formation.
In a literature review of children having undergone a Fontan-type operation, Michelson and coworkers
24 found 26 publications dealing with 486 patients. Only 3 of the included publications reported the use of antithrombotic therapy.
Today the role of long-term anticoagulation with warfarin remains controversial. No consensus is found in the literature or routine clinical practice about the optimal type or duration of anticoagulation.
6 Predominantly, patients with low cardiac output, with or without residual right-to-left shunting, are thought to benefit from anticoagulation.
At most cardiac centers, a wide variety of prophylactic anticoagulation regimens exists, ranging from no antiplatelet therapy in asymptomatic patients up to a life-long regimen of anticoagulation therapy with warfarin in all patients having undergone a Fontan operation.
9,11,15,25 Virtually no information regarding the safety and efficacy or the duration of prophylactic oral anticoagulation therapy exists. Because randomized, controlled, prospective trials are not available, statistically based guidelines for the management of children and adolescents after Fontan-like operations do not exist.
6
The use of anticoagulant therapy has always been weighed against the risk of hemorrhagic complications. Rosenthal and coworkers
9 estimated an approximately constant hazard rate of 3.9 bleeding events per 100 patient-years. Apart from the therapeutic aspects, a "good Fontan adolescent" will struggle against any medication that distances him or her further from normality to maintain his or her self-esteem and will tend to neglect his or her medical history and current problems.
2
At our institution, we keep the INR target levels in patients after a modified Fontan operation between 3.0 and 4.5. The recommendations for an appropriate INR for children may be lower than that found in adults,
24,26,27 but the optimal INR to prevent thrombus formation in children having undergone a Fontan operation remains unclear, and recommendations are usually defined according to the experience with patients after prosthetic valve operations.
Of the 7 patients who were receiving oral anticoagulation therapy, 2 were shown to have an intracardiac thrombus formation. At the time of our study, one of these patients had an INR of 2.5, and the other had an INR of 2.0. Both were symptom-free. An additional anticoagulation disorder could not be diagnosed in these patients.
Jahangiri and colleagues
11 described one patient with left-sided hemiparesis after administration of warfarin (INR 2.8), and a similar case was reported by Danielson in his comment. The incidence of venous thrombosis despite prophylactic oral anticoagulation with warfarin, as published by Jonas
10 in 1995, was 7.4%.
| Conclusion |
|---|
|
|
|---|
The incidence of thrombosis despite oral anticoagulation remains unknown. We were unable to define anatomic, laboratory, or hemodynamic risk factors. Thrombus formation seems to be unpredictable in the postoperative course. The preliminary data of this study may justify the recommendation of oral anticoagulation prophylaxis in patients having undergone a Fontan operation. The outcome of clinical studies with a controlled, prospective, randomized design should allow us to conclude whether life-long prophylaxis is indicated and to determine the optimal INR target level. For all patients without anticoagulation medication or inadequate INRs, we would suggest a TEE screening for thrombosis.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
P. Monagle, E. Chalmers, A. Chan, G. deVeber, F. Kirkham, P. Massicotte, and A. D. Michelson Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 887S - 968S. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. C. Odegard, D. Zurakowski, S. Hornykewycz, J. A. DiNardo, R. A. Castro, E. J. Neufeld, and P. C. Laussen Evaluation of the Coagulation System in Children with Two-Ventricle Congenital Heart Disease Ann. Thorac. Surg., May 1, 2007; 83(5): 1797 - 1803. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Guay Invited commentary Ann. Thorac. Surg., May 1, 2007; 83(5): 1803 - 1804. [Full Text] [PDF] |
||||
![]() |
H A Walker and M A Gatzoulis Prophylactic anticoagulation following the Fontan operation Heart, July 1, 2005; 91(7): 854 - 856. [Full Text] [PDF] |
||||
![]() |
R Kaulitz and M Hofbeck Current treatment and prognosis in children with functionally univentricular hearts Arch. Dis. Child., July 1, 2005; 90(7): 757 - 762. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Ghaferi and G. M. Hutchins Progression of liver pathology in patients undergoing the Fontan procedure: Chronic passive congestion, cardiac cirrhosis, hepatic adenoma, and hepatocellular carcinoma J. Thorac. Cardiovasc. Surg., June 1, 2005; 129(6): 1348 - 1352. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Jacobs The Fontan operation, thromboembolism, and anticoagulation: A reappraisal of the single bullet theory J. Thorac. Cardiovasc. Surg., March 1, 2005; 129(3): 491 - 495. [Full Text] [PDF] |
||||
![]() |
R. Kaulitz, G. Ziemer, R. Rauch, M. Girisch, H. Bertram, A. Wessel, and M. Hofbeck Prophylaxis of thromboembolic complications after the Fontan operation (total cavopulmonary anastomosis) J. Thorac. Cardiovasc. Surg., March 1, 2005; 129(3): 569 - 575. [Abstract] [Full Text] [PDF] |
||||
![]() |
V Chaloupecky, I Svobodova, I Hadacova, V Tomek, B Hucin, T Tlaskal, J Janousek, O Reich, and J Skovranek Coagulation profile and liver function in 102 patients after total cavopulmonary connection at mid term follow up Heart, January 1, 2005; 91(1): 73 - 79. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Monagle, A. Chan, P. Massicotte, E. Chalmers, and A. D. Michelson Antithrombotic Therapy in Children*: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 645S - 687S. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Weipert, C. Noebauer, C. Schreiber, M. Kostolny, B. Zrenner, A. Wacker, J. Hess, and R. Lange Occurrence and management of atrial arrhythmia after long-term Fontan circulation J. Thorac. Cardiovasc. Surg., February 1, 2004; 127(2): 457 - 464. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Weinstein, C. Cua, D. Chan, and J. T. Davis Outcome of symptomatic patients undergoing extracardiac Fontan conversion and cryoablation J. Thorac. Cardiovasc. Surg., August 1, 2003; 126(2): 529 - 536. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Varma, M. R. Warr, A. L. Hendler, N. S. Paul, G. D. Webb, and J. Therrien Prevalence of "silent" pulmonary emboli in adults after the Fontan operation J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2252 - 2258. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. C. Odegard, F. X. McGowan Jr, D. Zurakowski, J. A. DiNardo, R. A. Castro, P. J. del Nido, and P. C. Laussen Procoagulant and anticoagulant factor abnormalities following the Fontan procedure: Increased factor VIII may predispose to thrombosis J. Thorac. Cardiovasc. Surg., June 1, 2003; 125(6): 1260 - 1267. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Woods, U. Dyamenahalli, B. W. Duncan, G. L. Rosenthal, and F. M. Lupinetti Comparison of extracardiac Fontan techniques: Pedicled pericardial tunnel versus conduit reconstruction J. Thorac. Cardiovasc. Surg., March 1, 2003; 125(3): 465 - 471. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Seipelt, A. Franke, J. F. Vazquez-Jimenez, P. Hanrath, G. von Bernuth, B. J. Messmer, and E. G. Muhler Thromboembolic complications after Fontan procedures: comparison of different therapeutic approaches Ann. Thorac. Surg., August 1, 2002; 74(2): 556 - 562. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K. Triedman, M. E. Alexander, B. A. Love, K. K. Collins, C. I. Berul, L. M. Bevilacqua, and E. P. Walsh Influence of patient factors and ablative technologies on outcomes of radiofrequency ablation of intra-atrial re-entrant tachycardia in patients with congenital heart disease J. Am. Coll. Cardiol., June 5, 2002; 39(11): 1827 - 1835. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. C. Odegard, F. X. McGowan Jr, D. Zurakowski, J. A. DiNardo, R. A. Castro, P. J. del Nido, and P. C. Laussen Coagulation factor abnormalities in patients with single-ventricle physiology immediately prior to the fontan procedure Ann. Thorac. Surg., June 1, 2002; 73(6): 1770 - 1777. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. C. Odegard, F. X. McGowan Jr, J. A. DiNardo, R. A. Castro, D. Zurakowski, C. M. Connor, D. D. Hansen, E. J. Neufeld, P. J. del Nido, and P. C. Laussen Coagulation abnormalities in patients with single-ventricle physiology precede the Fontan procedure J. Thorac. Cardiovasc. Surg., March 1, 2002; 123(3): 459 - 465. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. D. Coon, J. Rychik, R. T. Novello, P. S. Ro, J. W. Gaynor, and T. L. Spray Thrombus formation after the Fontan operation Ann. Thorac. Surg., June 1, 2001; 71(6): 1990 - 1994. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Stamm, I. Friehs, J. E. Mayer Jr, D. Zurakowski, J. K. Triedman, A. M. Moran, E. P. Walsh, J. E. Lock, R. A. Jonas, and P. J. del Nido Long-term results of the lateral tunnel Fontan operation J. Thorac. Cardiovasc. Surg., January 1, 2001; 121(1): 0028 - 41. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |